ArticleThe mental health clinician2020
Management of treatment-resistant generalized anxiety disorder.
Article in The mental health clinician, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Repetitive Transcranial Magnetic Stimulation for Generalized Anxiety Disorder: A Systematic Literature Review and Meta-Analysis.The international journal of neuropsychopharmacology · 2022Pooled it
- Associations between expected and observed psychological responses to acute resistance exercise in analogue generalized anxiety disorder.Scientific reports · 2025Trial
- Climbing as an Add-On Treatment Option for Patients with Severe Anxiety Disorders and PTSD: Feasibility Analysis and First Results of a Randomized Controlled Longitudinal Clinical Pilot Trial.International journal of environmental research and public health · 2022Trial
- Targeting miR-124-3p to Induce Antidepressant-Like Effects in Female Mice: MicroRNA Modulation of Stress Resilience.The European journal of neuroscience · 2026Article
- The 'Nature Impact' feasibility study protocol: a mixed methods feasibility study of a group- and nature-based health intervention for adults experiencing mild to moderate anxiety, depression and/or stress.Pilot and feasibility studies · 2026Article
- Towards Mechanism-Informed Treatments for Mental Health.Journal of neurochemistry · 2026Review
- The Therapeutic Home Environment for Chronic Diseases: A Transdisciplinary Ecosystem for Achieving Migraine Freedom and Managing Comorbid Anxiety, Insomnia, and Chronic Pain.Healthcare (Basel, Switzerland) · 2026Article
- Article
- Repetitive transcranial magnetic stimulation: advances for psychiatric disorders.Frontiers in psychiatry · 2026Review
- Acute psilocybin or ethocybin leads to a sustained increase in Pavlovian aversion memory in male mice.Frontiers in pharmacology · 2026Article
- Reduced Serum Soluble L-Selectin Levels but Not PCSK9 May Be Associated With Generalized Anxiety Disorder: A Case-Control Study.Journal of clinical laboratory analysis · 2026Article
- Altered serum interleukin-4 and monocyte chemoattractant protein-3 levels are associated with generalized anxiety disorder: a case-control study.Experimental biology and medicine (Maywood, N.J.) · 2026Article
- Psilocybin Enhances Cued Fear Extinction and Extinction Recall in Stress-Naïve, Acutely Stressed, and Chronically Stressed Mice.ACS pharmacology & translational science · 2025Article
- Prefrontal cortex astrocytes modulate distinct neuronal populations to control anxiety-like behavior.Nature communications · 2025Article
- Machine learning-based prediction of anxiety disorders using blood metabolite and social trait data from the UK Biobank.Brain, behavior, & immunity - health · 2025Article
- Immune Dysregulation in Depression and Anxiety: A Review of the Immune Response in Disease and Treatment.Cells · 2025Review
- Scaling of Ventral Hippocampal Activity during Anxiety.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- Assessing uptake of the core outcome set in anxiety disorder clinical trials: a cross-sectional analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Altered serum interleukin-17A and interleukin-23A levels may be associated with the pathophysiology and development of generalized anxiety disorder.Scientific reports · 2024Article
- Personalized brain circuit scores identify clinically distinct biotypes in depression and anxiety.Nature medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Generalized anxiety disorder (GAD) is characterized by persistent and excessive worry. Around half of the patients treated for GAD will fail to respond to initial treatment. Treatment-resistant (or refractory) GAD is defined as failure to respond to at least 1 trial of antidepressant therapy at adequate dose and duration. Review of the literature indicates several potential medication classes and individual agents that can be used as augmentation strategies to treat residual symptoms when recommended therapy per clinical practice guidelines fails. A thorough literature search revealed 2 medication classes with the largest amount of data to support their use in treatment-resistant GAD treatment: gamma-aminobutyric acid-related agents and atypical antipsychotics. This article focuses on evidence-based recommendations for the use of these agents as adjunctive therapies for patients with treatment-resistant GAD. Different pharmacologic approaches to use these agents are demonstrated through 2 patient cases in which patients have failed first-line treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.